

ADLM 2024

Knowledge, Innovation, and Networking



Photo: Waters Corporation

The Association for Diagnostics and Laboratory Medicine (ADLM) 2024 Conference in Chicago, IL took place July 28 - August 1 and attracted more than 18,000 attendees. This was a pivotal event for anyone involved in laboratory medicine and clinical diagnostics and brought together industry giants and innovative newcomers to offer a comprehensive look at where the field is headed. Here are some of the highlights we noticed:

Pending LDT Regulations

One of the key discussions was around the FDA's new regulations governing Laboratory Developed Tests (LDTs). For some patient populations (rare diseases, pediatric and oncology, for example) LDTs comprise up to 20% of the total diagnostics testing pool. The more aggressive shift in the FDA's posture regarding LDTs raises over the past year softened a bit earlier this year, but concerns remain from the perspective of physicians and manufacturers of products used in the development of LDTs. The common theme for all those affected by impending regulations was to identify a path to preparedness that supports labs and patients in the wide variety of laboratory types that exist in this industry.

Syndromic Panel Testing

The evolution of syndromic panel testing was another key topic of discussion. Companies like [bioMérieux](#) and [Diasorin](#) showcased their latest advancements, emphasizing the importance of rapid, comprehensive testing solutions aimed at improving patient outcomes. While [bioMérieux](#) is trailblazing with the 15-minute turn-around-times of SpotFire testing, [Diasorin](#) is increasing testing flexibility with the LIAISON FLEX and easing reimbursement navigation.



Lab Automation and Other Trends

Laboratory automation had a large expo footprint and global representation. Patient sample handling, clinical chemistry, and molecular diagnostics powerhouses like [Hamilton](#), [Abbott](#), [Brooks](#), [Stago](#), [Sarstedt](#), and [Tecan](#) showcased their technological advances and efforts to remove the potential for human error in diagnostic testing. An equally interesting presence was put forward by players like [IDS](#), [Seegene](#), [Sunbio](#), and



Anbio demonstrating their capabilities and pronouncing themselves as legitimate competition in this space.

The representation of lateral flow technology showed that despite having been around for decades, the field is far from stagnant. The ongoing improvements in sensitivity, specificity, and the sheer number of analytes developers fitting onto a single strip are setting the stage for its continued growth in point-of-care testing.

Clinical mass spectrometry was also exhibited by Roche, Waters, and Bruker. The potential applications in areas like personalized medicine are particularly exciting, but these manufacturers need to keep an eye on the FDA's LDT regulations for the potential impact on clinical mass spectrometry.

Finding the right partners across the IVD development continuum can drastically impact the success of a new technology. The conference featured a robust presence from suppliers and service providers essential to the creation of IVDs. From raw materials providers to microfluidics engineers, the ecosystem supporting this field is dynamic and essential.

In short, ADLM 2024 was a whirlwind of knowledge, innovation, and networking. The conference fostered new insights, stronger connections, and a renewed excitement for what's next in laboratory medicine and clinical diagnostics. The future is bright with better, faster, and more reliable diagnostics!



Greg Thompson
Partner
greg@brbradv.com



Frank Criscione
Manager
frank@brbradv.com



BROADBRANCH
ADVISORS